Decoding Dupuytren's Disease: How Embryonic Cells and Blood Pressure Pathways Could Hold the Key to New Treatments
"New research uncovers potential links between embryonic stem cells, blood pressure regulation, and Dupuytren's disease, offering hope for more effective, non-surgical therapies."
Dupuytren's disease (DD) is a condition that affects the hands, causing the tissue under the skin of the palm to thicken and tighten. This can lead to the fingers bending inwards towards the palm, making it difficult to straighten them. While not life-threatening, DD can significantly impact a person's quality of life, affecting their ability to perform everyday tasks.
Currently, treatments for DD, such as surgery and injections, often come with high recurrence rates and potential complications. Scientists are actively searching for new and more effective ways to manage this condition, focusing on the underlying biological processes that contribute to its development.
A groundbreaking study published in Plastic and Reconstructive Surgery Global Open has shed light on a potential link between DD, embryonic stem cell-like populations, and the renin-angiotensin system (RAS). The RAS is known for its role in regulating blood pressure and mediating fibrosis (scarring) in organs like the heart and kidneys. This unexpected connection opens up exciting new avenues for developing targeted therapies for DD.
Disease Burden and Treatment Trends
Dupuytren disease is a fibroproliferative disorder that can cause progressive hand contractures and functional impairment. Treatment options range from minimally invasive procedures to surgical interventions, but long-term trends in treatment utilization and reimbursement remain incompletely characterized. A 2015-to-2024 review used ICD-10 and CPT codes to examine trends in disease incidence and treatment modalities.
Treatment Options and Uncertainty
Non-surgical therapies broaden management options, particularly for early-stage nodular disease or mild-to-moderate contractures in patients seeking alternatives to open surgery. However, these treatments vary considerably in durability, recurrence rates, and supporting evidence. A systematic review also noted that hand therapy is not routinely provided before surgery, while another source reports that no gold-standard hand-therapy treatment exists for active disease.
From Early Records to Modern Reviews
Dupuytren’s disease has a long historical record and has been associated with Norse folklore, legends from the Western Isles of Scotland, and Christianity. The British Dupuytren’s Society identifies the first written medical record as a 1614 examination in Basel, Switzerland, by Felix Platter, who described a stonemason with contracted left ring and little fingers. Modern reviews describe the condition as involving nodule formation and contracture of the palmar fascia, with resulting finger deformity and loss of hand function.
The Surprising Role of Embryonic Stem Cells and Blood Pressure in Dupuytren's Disease
The study, conducted by researchers at the Gillies McIndoe Research Institute, investigated the expression of RAS components in tissue samples from patients with DD. They used a variety of techniques, including immunohistochemistry (IHC) staining, Western blotting (WB), and NanoString mRNA analysis, to examine the presence and activity of key proteins and genes involved in the RAS pathway.
- IHC Staining: Showed the presence of PRR, ACE, ATIIR1, and ATIIR2 on the ERG+ and CD34+ endothelium (the inner lining) of microvessels surrounding the DD cords and nodules. PRR was also found on the pericytes, which are cells that wrap around blood vessels and help to stabilize them.
- Western Blotting: Confirmed the protein expression of PRR, ACE, and ATIIR2, but not ATIIR1.
- NanoString Analysis: Showed transcriptional activation (increased gene activity) of PRR, ACE, and ATIIR1, but ATIIR2 expression was below detectable levels.
Cellular Origins and Angiotensin Pathways
A state-of-the-art review identifies several possible cellular contributors to Dupuytren’s disease, including pericytes, adipocytes, peri-nodular dermal cells, and stem cells. Layton and colleagues identified subsets of pericytes transitioning to myofibroblasts using CyTOF and single-cell RNA sequencing. Separately, angiotensin II receptor blockers have been proposed as a potential pharmacologic treatment because they can inhibit TGF-β1 upstream in several disease processes, while the AT1R pathway has been reported as upregulated in other fibrotic disorders.
Limits of the Current Evidence
Evidence for a renin-angiotensin-system connection is not uniformly positive: one study reported that ATIIR1 was not detected in any of three sets of Dupuytren disease samples examined. Severe disease also presents practical treatment challenges, because younger patients and those with a strong diathesis may experience higher recurrence rates after treatment. These findings support a cautious interpretation of proposed molecular targets and underscore the difficulty of achieving durable control in severe disease.
What This Means for the Future of Dupuytren's Disease Treatment
The discovery of a potential link between the RAS and embryonic stem cell-like populations in DD opens new possibilities for treatment. By targeting specific components of the RAS, researchers may be able to develop therapies that can prevent or reverse the progression of DD. More research is needed to determine exactly how the RAS influences the behavior of these cells and whether modulating RAS activity can effectively treat DD in humans.
Balancing Effectiveness and Recurrence
A review of 17 studies involving 1,010 patients compared percutaneous needle fasciotomy, collagenase clostridium histolyticum, and limited fasciectomy. The study reported that all three methods were similarly effective in reducing contracture over the long term. Limited fasciectomy had the lowest recurrence rate among the treatments reviewed, illustrating the need to balance immediate effectiveness, safety, and durability.
Toward More Individualized Care
A survey of hand surgeons found that indications for intervention are influenced by disease location and extent, surgeon preference, and comfort with different treatment techniques. These factors suggest that future management will need to account for variation in clinical decision-making rather than rely on a single universal approach. A 2026 market report describes continued growth associated with orthopedic care, regenerative medicine, and minimally invasive treatment options, although that projection is not itself evidence of clinical effectiveness.
A Surgical Legacy
Surgery was the first treatment for Dupuytren’s contracture. The historical account of treatment identifies Guillaume Dupuytren as the surgeon associated with that early approach. For many years afterward, doctors continued to follow his method of managing the disease.
Recovery Matters to Patients
Research on patient experiences shows that how treatment is understood and experienced is an important part of care. Patients may be willing to accept some reduction in clinical benefit in exchange for a shorter treatment and quicker recovery. This finding highlights that treatment decisions involve patient priorities as well as clinical outcomes.